Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847349 · ClinicalTrials.gov registry record · NA
Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT04847349 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 54 participants.
The verdict
NCT04847349, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
This pilot double-blind randomized controlled trial will test the preliminary efficacy of two doses of a combination of live microbials (probiotics) given to boost the immunity of unvaccinated persons previously infected with SARS-CoV-2.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT OL-1, standard dose
- DIETARY_SUPPLEMENT OL-1, high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2022-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847349
The ClinicalTrials.gov registry entry for NCT04847349 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04847349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847349 about?
NCT04847349 is a clinical study titled "Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial". This pilot double-blind randomized controlled trial will test the preliminary efficacy of two doses of a combination of live microbials (probiotics) given to boost the immunity of unvaccinated persons previously infected with SARS-CoV-2.
What is the current status of trial NCT04847349?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2021-04-13. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04847349?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), OL-1, standard dose (DIETARY_SUPPLEMENT), OL-1, high dose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04847349?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.